These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1074 related items for PubMed ID: 19672772

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study.
    Wu L, Li X, Chang C, Xu F, He Q, Wu D, Zhang Z, Su J, Zhou L, Song L, Chao X, Zhao Y.
    Leuk Lymphoma; 2016; 57(6):1367-74. PubMed ID: 26397697
    [Abstract] [Full Text] [Related]

  • 5. HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants.
    Xie M, Jiang Q, Li L, Zhu J, Zhu L, Zhou D, Zheng Y, Yang X, Zhu M, Sun J, Xie W, Ye X.
    PLoS One; 2016; 11(10):e0164238. PubMed ID: 27706258
    [Abstract] [Full Text] [Related]

  • 6. Effect of granulocyte colony-stimulating factor priming combined with low-dose cytarabine and homoharringtonine in higher risk myelodysplastic syndrome patients.
    Wang FX, Zhang WG, He AL, Cao XM, Chen YX, Zhao WH, Yang Y, Wang JL, Zhang PY, Gu LF.
    Leuk Res; 2016 Sep; 48():57-61. PubMed ID: 27497340
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A.
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J, Lv TT, Zhou XF, Huang Y, Liu DD, Yuan GL.
    Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
    [Abstract] [Full Text] [Related]

  • 14. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
    Becker PS, Medeiros BC, Stein AS, Othus M, Appelbaum FR, Forman SJ, Scott BL, Hendrie PC, Gardner KM, Pagel JM, Walter RB, Parks C, Wood BL, Abkowitz JL, Estey EH.
    Am J Hematol; 2015 Apr; 90(4):295-300. PubMed ID: 25545153
    [Abstract] [Full Text] [Related]

  • 15. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X, Mei C, Zhang J, Lu Y, Lan J, Lin S, Zhang Y, Kuang Y, Ren Y, Ma L, Wei J, Ye L, Xu W, Li K, Lu C, Jin J, Tong H.
    Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
    [Abstract] [Full Text] [Related]

  • 16. [Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in MDS-EB and AML-MRC].
    Liu J, Jia JS, Gong LZ, Lu SY, Zhu HH, Huang XJ, Jiang H.
    Zhonghua Xue Ye Xue Za Zhi; 2018 Sep 14; 39(9):734-738. PubMed ID: 30369183
    [Abstract] [Full Text] [Related]

  • 17. A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
    Wrzesień-Kuś A, Robak T, Lech-Marańda E, Wierzbowska A, Dmoszyńska A, Kowal M, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Maj S, Hellmann A, Skotnicki A, Jedrzejczak W, Kuliczkowski K, Polish Adult Leukemia Group.
    Eur J Haematol; 2003 Sep 14; 71(3):155-62. PubMed ID: 12930315
    [Abstract] [Full Text] [Related]

  • 18. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
    Liu L, Qu Q, Jiao W, Zhang Y, Li X, Ding C, Wu D.
    Leuk Res; 2015 Aug 14; 39(8):805-11. PubMed ID: 26021434
    [Abstract] [Full Text] [Related]

  • 19. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients.
    Li JM, Shen Y, Wu DP, Liang H, Jin J, Chen FY, Song YP, Song EY, Qiu XF, Hou M, Qiu ZC, Shen ZX.
    Int J Hematol; 2005 Jul 14; 82(1):48-54. PubMed ID: 16105759
    [Abstract] [Full Text] [Related]

  • 20. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G, Graf N, Hasan C, Ackermann M, Breu H, Zernikow B, Bode U.
    Klin Padiatr; 1996 Jul 14; 208(4):229-35. PubMed ID: 8926688
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.